SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Cannon Christopher P.)
 

Sökning: WFRF:(Cannon Christopher P.) > Comparison of ticag...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003734naa a2200409 4500
001oai:DiVA.org:uu-105112
003SwePub
008090601s2009 | |||||||||||000 ||eng|
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-1051122 URI
0247 a https://doi.org/10.1016/j.ahj.2009.01.0032 DOI
040 a (SwePub)uu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a James, Stefan,d 1964-u Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),kardiolig4 aut0 (Swepub:uu)stjam367
2451 0a Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes :b Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial
264 1b Elsevier BV,c 2009
338 a print2 rdacarrier
520 a BACKGROUND: Antiplatelet therapy is essential treatment for acute coronary syndromes (ACS). Current therapies, however, have important limitations affecting their clinical success. Ticagrelor, the first reversible oral P2Y(12) receptor antagonist, provides faster, greater, and more consistent adenosine diphosphate-receptor inhibition than clopidogrel. The phase III PLATelet inhibition and patient Outcomes (PLATO) trial is designed to test the hypothesis that ticagrelor compared with clopidogrel will result in a lower risk of recurrent thrombotic events in a broad patient population with ACS. METHODS: PLATO is an international, randomized, double-blind, event-driven trial involving >18,000 patients hospitalized for ST-elevation ACS with scheduled primary percutaneous coronary intervention or for non-ST-elevation ACS. After loading doses of ticagrelor 180 mg or clopidogrel 300 mg in a double-blind, double-dummy fashion (with provision for additional 300 mg clopidogrel at percutaneous coronary intervention), patients will receive ticagrelor 90 mg twice daily or clopidogrel 75 mg once daily for 6 to 12 months on top of acetylsalicylic acid. The primary efficacy end point is time to first occurrence of death from vascular causes, myocardial infarction, or stroke. The primary safety variable is PLATO-defined major bleeding. An extensive substudy program will explore the pathophysiology of ACS, indicators of prognosis and response to treatment, mechanisms of effect and safety of the study medications, health economics, and quality of life. CONCLUSION: The PLATO study will provide a pivotal comparison of the efficacy and safety of ticagrelor with those of clopidogrel in ACS patients, together with extensive information on treatment outcomes in different subsets of ACS in a broad patient population.
653 a MEDICINE
653 a MEDICIN
7001 a Åkerblom, Axelu Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),kardiologi4 aut0 (Swepub:uu)axeak985
7001 a Cannon, Christopher P.4 aut
7001 a Emanuelsson, Håkan4 aut
7001 a Husted, Steen4 aut
7001 a Katus, Hugo4 aut
7001 a Skene, Allan4 aut
7001 a Steg, Philippe Gabriel4 aut
7001 a Storey, Robert F.4 aut
7001 a Harrington, Robert4 aut
7001 a Becker, Richard4 aut
7001 a Wallentin, Lars,d 1943-u Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),kardiologi4 aut0 (Swepub:uu)larswall
7102 a Uppsala universitetb Uppsala kliniska forskningscentrum (UCR)4 org
7730 t American Heart Journald : Elsevier BVg 157:4, s. 599-605q 157:4<599-605x 0002-8703x 1097-6744
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-105112
8564 8u https://doi.org/10.1016/j.ahj.2009.01.003

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy